Advanced Targeting Systems

Advanced Targeting Systems is a private biotechnology firm founded in 1994, commercializing a proprietary platform centered on the ribosome-inactivating toxin Saporin. The company creates targeted conjugates that bind to specific cell surface receptors, enabling researchers to selectively ablate cell populations to model diseases like Alzheimer's and Parkinson's and study cell functionality. While primarily serving the neuroscience research community, its tools have broad applicability across life sciences research and drug development. ATS operates as a reagent supplier and service provider, generating revenue through product sales and custom conjugate services.

Saporin-based targeted toxin conjugates for selective cell ablation ('Molecular Surgery'). The platform uses the ribosome-inactivating toxin Saporin linked to targeting agents (antibodies, peptides, etc.) that bind specific cell surface receptors. Upon internalization, Saporin halts protein synthesis, killing only the targeted cells.

ATS occupies a specialized niche in targeted cytotoxins for research. Direct competitors are few but include companies like Lesion Laboratories and targeted toxin offerings from some antibody suppliers. Broader competition comes from providers of genetic cell manipulation tools (e.g., viral vectors for DREADDs/optogenetics from companies like Addgene) and large reagent conglomerates (e.g., Thermo Fisher, Abcam) that could develop similar conjugate services.